You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameMagnesium Sulfate
Accession NumberDB00653  (APRD01080)
TypeSmall Molecule
GroupsApproved
Description

A small colorless crystal used as an anticonvulsant, a cathartic, and an electrolyte replenisher in the treatment of pre-eclampsia and eclampsia. It causes direct inhibition of action potentials in myometrial muscle cells. Excitation and contraction are uncoupled, which decreases the frequency and force of contractions. (From AMA Drug Evaluations Annual, 1992, p1083)

Structure
Thumb
Synonyms
SynonymLanguageCode
Magnesium sulfate (1:1)Not AvailableNot Available
Magnesium sulfate anhydrousNot AvailableNot Available
Magnesium sulphateNot AvailableNot Available
Magnesium(ii) sulfateNot AvailableNot Available
MagnesiumsulfatNot AvailableNot Available
MgSO4Not AvailableNot Available
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Magnesium Sulfateinjection, solution4 g/100mLintravenousHospira, Inc.1994-06-24Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Magnesium Sulfateinjection, solution4 g/50mLintravenousHospira, Inc.1994-06-24Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Magnesium Sulfateinjection, solution500 mg/mLintramuscular; intravenousCardinal Health2000-08-08Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Magnesium Sulfateinjection, solution500 mg/mLintramuscular; intravenousFresenius Kabi USA, LLC2000-08-08Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Magnesium Sulfateinjection, solution500 mg/mLintramuscular; intravenousFresenius Kabi USA, LLC2000-08-08Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Magnesium Sulfateinjection, solution500 mg/mLintramuscular; intravenousHospira, Inc.2000-04-25Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Magnesium Sulfateinjection, solution5 g/10mLintramuscular; intravenousGeneral Injectables & Vaccines, Inc2010-08-01Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Magnesium Sulfateinjection, solution500 mg/mLintramuscular; intravenousPhysicians Total Care, Inc.2006-12-12Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Over the Counter Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Humco Epson Saltpowder, for solution1000 mg/goralHumco Holding Group, Inc.1998-03-25Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Epsom Salgranule, for solution1 g/goral; topicalVi Jon1998-07-15Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Epsom Saltgranule, for solution1 g/goral; topicalTarget Corporation1996-12-12Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Epsom Saltgranule, for solution1 g/goral; topicalSAFEWAY INC2002-11-12Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Morton Natural Epsom Saltgranule, for solution1 kg/kgoral; topicalMorton Salt, Inc.2012-09-01Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Epsom Saltgranule, for solution1 g/goral; topicalKroger Co.1993-10-21Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Epsom Saltgranule, for solution1 g/goral; topicalTOPCO ASSOCIATES, LLC1999-07-15Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Epsom Saltgranule, for solution1 g/goral; topicalShop Ko Stores Operating Co., Llc2009-06-05Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Epsom Saltcrystal1.81 kg/100kgoral; topicalCardinal Health2012-03-26Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Epsom Saltgranule, for solution1 g/goral; topicalSUPERVALU INC.2005-03-21Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Epsom Saltgranule, for solution1 g/goral; topicalWakefern Food Corp2014-05-01Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Royal Epsom Saltgranule, for solution1 kg/kgoralFilo America2014-10-29Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Epsom Salt Soaking Solutiongranule2.72 kg/2.72kgtopicalAdvanced Beauty Systems, Inc.2012-06-13Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Pepsom Salt Peppermintfor solution1 kg/kgtopicalThe Pepsom Group, Inc.2007-05-21Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Pepsom Flying P Epsom Saltfor solution1 kg/kgtopicalThe Pepsom Group, Inc.2009-11-09Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Natural Epsom Saltpowder10 g/10gtopicalMy Import USA Inc2014-10-09Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Health Smart Natural Epsom Saltgranule, for solution1 g/goralInternational Wholesale, Inc.2013-08-01Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Health Smart Natural Epsom Saltgranule, for solution1 g/goralInternational Wholesale, Inc.2013-08-01Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Epsom Saltgranule, for solution1 g/goral; topicalDiscount Drug Mart2002-12-02Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Epsom Saltgranule, for solution1 g/goral; topicalYour Military Exchange2002-12-18Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Epsom Saltgranule100 kg/100kgoralWestern Family1998-06-05Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Epsom Saltgranule, for solution1 g/goral; topicalDZA Brands, LLC2008-02-27Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Epsom Saltgranule, for solution1 g/goral; topicalDolgencorp, LLC1993-10-21Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Epsom Saltgranule, for solution1 g/goral; topicalPublix Super Markets, Inc2014-09-05Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Epsom Saltgranule1 g/goralPublix Super Markets, Inc.,2013-07-03Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Epsom Salt Magnesium Sulfategranule1 g/goral; topicalCVS Pharmacy2014-12-31Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Epsom Saltgranule, for solution1 g/goral; topicalValu Merchandisers, Co.2014-10-15Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Natural Epsom Saltpowder10 g/10gtopicalAnhui Twowin Machinery Imp. & Exp. Co., Ltd.2014-10-09Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Epsom Saltgranule, for solution1 g/goral; topicalGeiss, Destin and Dunn, Inc1992-07-15Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
International BrandsNot Available
Brand mixturesNot Available
SaltsNot Available
Categories
CAS number7487-88-9
WeightAverage: 120.368
Monoisotopic: 119.936771076
Chemical FormulaMgO4S
InChI KeyCSNNHWWHGAXBCP-UHFFFAOYSA-L
InChI
InChI=1S/Mg.H2O4S/c;1-5(2,3)4/h;(H2,1,2,3,4)/q+2;/p-2
IUPAC Name
magnesium(2+) ion sulfate
SMILES
[Mg++].[O-]S([O-])(=O)=O
Taxonomy
DescriptionThis compound belongs to the class of inorganic compounds known as alkaline earth metal sulfates. These are inorganic compounds in which the largest oxoanion is sulfate, and in which the heaviest atom not in an oxoanion is an alkaline earth metal.
KingdomInorganic compounds
Super ClassMixed metal/non-metal compounds
ClassAlkaline earth metal oxoanionic compounds
Sub ClassAlkaline earth metal sulfates
Direct ParentAlkaline earth metal sulfates
Alternative Parents
Substituents
  • Alkaline earth metal sulfate
  • Inorganic oxide
  • Inorganic salt
  • Acyclic compound
Molecular FrameworkAcyclic compounds
External Descriptors
Pharmacology
IndicationUsed for immediate control of life-threatening convulsions in the treatment of severe toxemias (pre-eclampsia and eclampsia) of pregnancy and in the treatment of acute nephritis in children. Also indicated for replacement therapy in magnesium deficiency, especially in acute hypomagnesemia accompanied by signs of tetany similar to those of hypocalcemia. Also used in uterine tetany as a myometriat relaxant.
PharmacodynamicsMagnesium sulfate is a small colorless crystal used as an anticonvulsant, a cathartic, and an electrolyte replenisher in the treatment of pre-eclampsia and eclampsia. It causes direct inhibition of action potentials in myometrial muscle cells. Excitation and contraction are uncoupled, which decreases the frequency and force of contractions. Magnesium sulfate is gaining popularity as an initial treatment in the management of various dysrhythmias, particularly torsades de pointes, and dyrhythmias secondary to TCA overdose or digitalis toxicity.
Mechanism of actionMagnesium is the second most plentiful cation of the intracellular fluids. It is essential for the activity of many enzyme systems and plays an important role with regard to neurochemical transmission and muscular excitability. Magnesium sulfate reduces striated muscle contractions and blocks peripheral neuromuscular transmission by reducing acetylcholine release at the myoneural junction. Additionally, Magnesium inhibits Ca2+ influx through dihydropyridine-sensitive, voltage-dependent channels. This accounts for much of its relaxant action on vascular smooth muscle.
AbsorptionNot Available
Volume of distributionNot Available
Protein binding25-30%
Metabolism

None

Route of eliminationMagnesium is excreted solely by the kidney at a rate proportional to the serum concentration and glomerular filtration.
Half life43.2 hours (for newborns)
ClearanceNot Available
ToxicityLD50 = 1200 mg/kg (rat, subcutaneous). May be harmful if swallowed. May act as an irritant. Adverse reactions include hypotension, ECG changes, diarrhea, urinary retention, CNS depression and respiratory depression.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.7487
Blood Brain Barrier+0.9646
Caco-2 permeable-0.6267
P-glycoprotein substrateNon-substrate0.9137
P-glycoprotein inhibitor INon-inhibitor0.9194
P-glycoprotein inhibitor IINon-inhibitor0.9904
Renal organic cation transporterNon-inhibitor0.9521
CYP450 2C9 substrateNon-substrate0.8775
CYP450 2D6 substrateNon-substrate0.8213
CYP450 3A4 substrateNon-substrate0.7007
CYP450 1A2 substrateNon-inhibitor0.7767
CYP450 2C9 substrateNon-inhibitor0.7602
CYP450 2D6 substrateNon-inhibitor0.9115
CYP450 2C19 substrateNon-inhibitor0.7547
CYP450 3A4 substrateNon-inhibitor0.9759
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9577
Ames testNon AMES toxic0.5773
CarcinogenicityCarcinogens 0.8111
BiodegradationReady biodegradable0.943
Rat acute toxicity2.4160 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.7988
hERG inhibition (predictor II)Non-inhibitor0.9446
Pharmacoeconomics
Manufacturers
  • Abraxis pharmaceutical products
  • Hospira inc
Packagers
Dosage forms
FormRouteStrength
Crystaloral; topical1.81 kg/100kg
For solutiontopical1 kg/kg
Granuleoral1 g/g
Granuleoral100 kg/100kg
Granuleoral; topical1 g/g
Granuletopical2.72 kg/2.72kg
Granule, for solutionoral1 g/g
Granule, for solutionoral1 kg/kg
Granule, for solutionoral; topical1 g/g
Granule, for solutionoral; topical1 kg/kg
Injection, solutionintramuscular; intravenous5 g/10mL
Injection, solutionintramuscular; intravenous500 mg/mL
Injection, solutionintravenous4 g/100mL
Injection, solutionintravenous4 g/50mL
Powdertopical10 g/10g
Powder, for solutionoral1000 mg/g
Prices
Unit descriptionCostUnit
Elliotts b solution ampule4.71USD ml
Magnesium Sulfate 50% Solution 2ml Vial0.92USD vial
Magnesium sulfate powder0.29USD g
Magnesium-ns 6 g/50 ml bag0.29USD ml
Magnesium-ns 4 g/50 ml bag0.27USD ml
Magnesium-ns 3 g/50 ml bag0.26USD ml
Magnesium sulfate-ns 2 gm bag0.25USD ml
Magnesium sulfate-ns 1 gm bag0.24USD ml
Magnesium-d5w 1 gm/100 ml soln0.07USD ml
Magnesium-lr 20 g/500 ml0.03USD ml
Magnesium-lr 40 g/500 ml bag0.03USD ml
Magnesium-lr 50 g/500 ml bag0.02USD ml
Epsom salt 100% powder0.01USD g
Magnesium sulf 4% iv soln0.01USD ml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point1124 °C (decomposition)Not Available
water solubility710 mg/mLNot Available
logP-0.91Not Available
Predicted Properties
PropertyValueSource
logP-0.84ChemAxon
pKa (Strongest Acidic)-3ChemAxon
Physiological Charge-2ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area80.26 Å2ChemAxon
Rotatable Bond Count0ChemAxon
Refractivity11.53 m3·mol-1ChemAxon
Polarizability5.81 Å3ChemAxon
Number of Rings0ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
SpectraNot Available
References
Synthesis Reference

Shinichi Yamamoto, Akifumi Sekitani, “BASIC MAGNESIUM SULFATE GRANULE, AND PROCESS FOR PRODUCTION THEREOF.” U.S. Patent US20110042297, issued February 24, 2011.

US20110042297
General Reference
  1. Blitz M, Blitz S, Hughes R, Diner B, Beasley R, Knopp J, Rowe BH: Aerosolized magnesium sulfate for acute asthma: a systematic review. Chest. 2005 Jul;128(1):337-44. Pubmed
  2. Yokoyama K, Takahashi N, Yada Y. Prolonged maternal magnesium administration and bone metabolism in neonates. Early Hum Dev. 2010;86(3):187-91. Epub 2010 Mar 12.
  3. Wedig KE, Kogan J, Schorry EK et al. Skeletal demineralization and fractures caused by fetal magnesium toxicity. J Perinatol. 2006; 26(6):371-4.
  4. Nassar AH, Sakhel K, Maarouf H, et al. Adverse maternal and neonatal outcome of prolonged course of Magnesium Sulfate tocolysis. Acta Obstet Gynecol Scan. 2006;85(9):1099-103.
  5. Malaeb SN, Rassi A, Haddad MC. Bone mineralization in newborns whose mothers received magnesium sulphate for tocolysis of premature labor. Pediatr Radiol. 2004;34(5):384-6. Epub 2004 Feb 18.
  6. Matsuda Y, Maeda Y, Ito M, et al. Effect of Magnesium Sulfate treatment on neonatal bone abnormalities. Gynecol Obstet Invest. 1997;44(2):82-8.
  7. Schanler RJ, Smith LG, Burns PA. Effects of long-term maternal intravenous Magnesium Sulfate therapy on neonatal calcium metabolism and bone mineral content. Gynecol Obstet Invest. 1997;43(4):236-41.
  8. Santi MD, Henry GW, Douglas GL. Magnesium Sulfate treatment of preterm labor as a cause of abnormal neonatal bone mineralization. J Pediatr Orthop. 1994;14(2):249-53.
  9. Holcomb WL, Shackelford GD, Petrie RH. Magnesium tocolysis and neonatal bone abnormalities: a controlled study. Obstet Gynecol. 1991; 78(4):611-4.
  10. Cumming WA, Thomas VJ. Hypermagnesemia: a cause of abnormal metaphyses in the neonate. Am J Roentgenol. 1989; 152(5):1071-2.
  11. Lamm CL, Norton KL, Murphy RJ. Congenital rickets associated with Magnesium Sulfate infusion for tocolysis. J Pediatr. 1988; 113(6):1078-82.
  12. McGuinness GA, Weinstein MM, Cruikshank DP, et al. Effects of Magnesium Sulfate treatment on perinatal calcium metabolism. II. Neonatal responses. Obstet Gynecol. 1980;56(5): 595-600.
  13. Riaz M, Porat R, Brodsky NL, et al. The effects of maternal Magnesium Sulfate treatment on newborns: a prospective controlled study. J Perinatol. 1998;18(6 pt 1):449-54.
External Links
ATC CodesA06AD04A12CC02B05XA05D11AX05V04CC02
AHFS Codes
  • 28:12.92
  • 40:12.00
  • 56:12.00
  • 84:92.00
  • 92:02.00*
PDB EntriesNot Available
FDA labelNot Available
MSDSDownload (72.1 KB)
Interactions
Drug Interactions
Drug
AlfentanilMay enhance the CNS depressant effect of CNS Depressants.
AlprazolamMay enhance the CNS depressant effect of CNS Depressants.
AmitriptylineMay enhance the CNS depressant effect of CNS Depressants.
AmobarbitalBarbiturates may increase the metabolism of Calcium Channel Blockers.
AmoxapineMay enhance the CNS depressant effect of CNS Depressants.
AripiprazoleMay enhance the CNS depressant effect of CNS Depressants.
AsenapineMay enhance the CNS depressant effect of CNS Depressants.
AtracuriumMay enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents (Nondepolarizing).
AzelastineMay enhance the CNS depressant effect of CNS Depressants.
BaclofenMay enhance the CNS depressant effect of CNS Depressants.
BrimonidineMay enhance the CNS depressant effect of CNS Depressants.
BromazepamMay enhance the CNS depressant effect of CNS Depressants.
BrompheniramineMay enhance the CNS depressant effect of CNS Depressants.
BuprenorphineMay enhance the CNS depressant effect of CNS Depressants.
BuspironeMay enhance the CNS depressant effect of CNS Depressants.
ButabarbitalBarbiturates may increase the metabolism of Calcium Channel Blockers.
ButalbitalBarbiturates may increase the metabolism of Calcium Channel Blockers.
ButorphanolMay enhance the CNS depressant effect of CNS Depressants.
Calcium AcetateCalcium Salts may diminish the therapeutic effect of Calcium Channel Blockers.
Calcium carbonateCalcium Salts may diminish the therapeutic effect of Calcium Channel Blockers.
Calcium ChlorideCalcium Salts may diminish the therapeutic effect of Calcium Channel Blockers.
CarbamazepineMay enhance the CNS depressant effect of CNS Depressants.
CarbinoxamineMay enhance the CNS depressant effect of CNS Depressants.
CarisoprodolMay enhance the CNS depressant effect of CNS Depressants.
CetirizineMay enhance the CNS depressant effect of CNS Depressants.
ChlordiazepoxideMay enhance the CNS depressant effect of CNS Depressants.
ChlorphenamineMay enhance the CNS depressant effect of CNS Depressants.
ChlorpromazineMay enhance the CNS depressant effect of CNS Depressants.
ChlorzoxazoneMay enhance the CNS depressant effect of CNS Depressants.
CimetidineCimetidine may increase the serum concentration of Calcium Channel Blockers.
Cisatracurium BesylateMay enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents (Nondepolarizing).
ClarithromycinMacrolide Antibiotics may decrease the metabolism of Calcium Channel Blockers.
ClemastineMay enhance the CNS depressant effect of CNS Depressants.
ClidiniumMay enhance the CNS depressant effect of CNS Depressants.
ClobazamMay enhance the CNS depressant effect of CNS Depressants.
ClomipramineMay enhance the CNS depressant effect of CNS Depressants.
ClonazepamMay enhance the CNS depressant effect of CNS Depressants.
ClonidineMay enhance the CNS depressant effect of CNS Depressants.
ClopidogrelMay diminish the therapeutic effect of Clopidogrel. Exceptions: Clevidipine.
ClozapineMay enhance the CNS depressant effect of CNS Depressants.
CodeineMay enhance the CNS depressant effect of CNS Depressants.
CyclizineMay enhance the CNS depressant effect of CNS Depressants.
CyclobenzaprineMay enhance the CNS depressant effect of CNS Depressants.
CyproheptadineMay enhance the CNS depressant effect of CNS Depressants.
DantroleneMay enhance the CNS depressant effect of CNS Depressants.
DesfluraneMay enhance the CNS depressant effect of CNS Depressants.
DesipramineMay enhance the CNS depressant effect of CNS Depressants.
DesloratadineMay enhance the CNS depressant effect of CNS Depressants.
DexbrompheniramineMay enhance the CNS depressant effect of CNS Depressants.
DiazepamMay enhance the CNS depressant effect of CNS Depressants.
DifenoxinMay enhance the CNS depressant effect of CNS Depressants.
DihydrocodeineMay enhance the CNS depressant effect of CNS Depressants.
DimenhydrinateMay enhance the CNS depressant effect of CNS Depressants.
DiphenoxylateMay enhance the CNS depressant effect of CNS Depressants.
DoxazosinAlpha1-Blockers may enhance the hypotensive effect of Calcium Channel Blockers.
DoxylamineMay enhance the CNS depressant effect of CNS Depressants.
DroperidolMay enhance the CNS depressant effect of CNS Depressants.
EnfluraneMay enhance the CNS depressant effect of CNS Depressants.
EntacaponeMay enhance the CNS depressant effect of CNS Depressants.
EstazolamMay enhance the CNS depressant effect of CNS Depressants.
EszopicloneMay enhance the CNS depressant effect of CNS Depressants.
EthosuximideMay enhance the CNS depressant effect of CNS Depressants.
EthotoinMay enhance the CNS depressant effect of CNS Depressants.
EzogabineMay enhance the CNS depressant effect of CNS Depressants.
FelbamateMay enhance the CNS depressant effect of CNS Depressants.
FentanylMay enhance the CNS depressant effect of CNS Depressants.
FexofenadineMay enhance the CNS depressant effect of CNS Depressants.
FluconazoleFluconazole may increase the serum concentration of Calcium Channel Blockers. Exceptions: Clevidipine.
FlunarizineMay enhance the CNS depressant effect of CNS Depressants.
FlupentixolMay enhance the CNS depressant effect of CNS Depressants.
FlurazepamMay enhance the CNS depressant effect of CNS Depressants.
Fluticasone PropionateMay enhance the CNS depressant effect of CNS Depressants.
FosphenytoinMay increase the serum concentration of Fosphenytoin.
gabapentin enacarbilMay enhance the CNS depressant effect of CNS Depressants.
Gamma Hydroxybutyric AcidMay enhance the CNS depressant effect of CNS Depressants.
GuanfacineMay enhance the CNS depressant effect of CNS Depressants.
HaloperidolMay enhance the CNS depressant effect of CNS Depressants.
HydrocodoneMay enhance the CNS depressant effect of CNS Depressants.
HydromorphoneMay enhance the CNS depressant effect of CNS Depressants.
HydroxyzineMay enhance the CNS depressant effect of CNS Depressants.
IloperidoneMay enhance the CNS depressant effect of CNS Depressants.
ImipramineMay enhance the CNS depressant effect of CNS Depressants.
IsofluraneMay enhance the CNS depressant effect of CNS Depressants.
ItraconazoleAntifungal Agents (Azole Derivatives, Systemic) may enhance the adverse/toxic effect of Calcium Channel Blockers. Specifically, itraconazole may enhance the negative inotropic effects of verapamil or diltiazem. Antifungal Agents (Azole Derivatives, Systemic) may decrease the metabolism of Calcium Channel Blockers. Fluconazole and isavuconazonium likely exert weaker effects than other azoles and are addressed in separate monographs.
KetamineMay enhance the CNS depressant effect of CNS Depressants.
KetotifenMay enhance the CNS depressant effect of CNS Depressants.
LamotrigineMay enhance the CNS depressant effect of CNS Depressants.
LevetiracetamMay enhance the CNS depressant effect of CNS Depressants.
LevocabastineMay enhance the CNS depressant effect of CNS Depressants.
LevocetirizineMay enhance the CNS depressant effect of CNS Depressants.
LevorphanolMay enhance the CNS depressant effect of CNS Depressants.
LoratadineMay enhance the CNS depressant effect of CNS Depressants.
LorazepamMay enhance the CNS depressant effect of CNS Depressants.
LoxapineMay enhance the CNS depressant effect of CNS Depressants.
LurasidoneMay enhance the CNS depressant effect of CNS Depressants.
Magnesium oxideMay enhance the adverse/toxic effect of Magnesium Salts. Magnesium Salts may enhance the hypotensive effect of Calcium Channel Blockers.
Magnesium salicylateMay enhance the adverse/toxic effect of Magnesium Salts. Magnesium Salts may enhance the hypotensive effect of Calcium Channel Blockers.
MaprotilineMay enhance the CNS depressant effect of CNS Depressants.
MeclizineMay enhance the CNS depressant effect of CNS Depressants.
MefloquineMefloquine may diminish the therapeutic effect of Anticonvulsants. Mefloquine may decrease the serum concentration of Anticonvulsants.
MeprobamateMay enhance the CNS depressant effect of CNS Depressants.
MethadoneMay enhance the CNS depressant effect of CNS Depressants.
MethocarbamolMay enhance the CNS depressant effect of CNS Depressants.
MethohexitalBarbiturates may increase the metabolism of Calcium Channel Blockers.
MethotrimeprazineMay enhance the CNS depressant effect of CNS Depressants.
MethsuximideMay enhance the CNS depressant effect of CNS Depressants.
MidazolamMay enhance the CNS depressant effect of CNS Depressants.
MirtazapineMay enhance the CNS depressant effect of CNS Depressants.
MorphineMay enhance the CNS depressant effect of CNS Depressants.
NafcillinNafcillin may increase the metabolism of Calcium Channel Blockers. Exceptions: Clevidipine.
NalbuphineMay enhance the CNS depressant effect of CNS Depressants.
NitrazepamMay enhance the CNS depressant effect of CNS Depressants.
NitroprussideMay enhance the hypotensive effect of Nitroprusside.
Nitrous oxideMay enhance the CNS depressant effect of CNS Depressants.
NortriptylineMay enhance the CNS depressant effect of CNS Depressants.
OlanzapineMay enhance the CNS depressant effect of CNS Depressants.
OlopatadineMay enhance the CNS depressant effect of CNS Depressants.
OrlistatOrlistat may decrease the serum concentration of Anticonvulsants. Exceptions: Fosphenytoin; PENTobarbital; Thiopental.
OrphenadrineMay enhance the CNS depressant effect of CNS Depressants.
OxazepamMay enhance the CNS depressant effect of CNS Depressants.
OxycodoneMay enhance the CNS depressant effect of CNS Depressants.
OxymorphoneMay enhance the CNS depressant effect of CNS Depressants.
PaliperidoneMay enhance the CNS depressant effect of CNS Depressants.
PancuroniumMay enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents (Nondepolarizing).
PentobarbitalBarbiturates may increase the metabolism of Calcium Channel Blockers.
PerampanelMay enhance the CNS depressant effect of CNS Depressants.
PerphenazineMay enhance the CNS depressant effect of CNS Depressants.
PethidineMay enhance the CNS depressant effect of CNS Depressants.
PhenobarbitalBarbiturates may increase the metabolism of Calcium Channel Blockers.
PhenoxybenzamineAlpha1-Blockers may enhance the hypotensive effect of Calcium Channel Blockers.
PhentolamineAlpha1-Blockers may enhance the hypotensive effect of Calcium Channel Blockers.
PhenytoinMay increase the serum concentration of Phenytoin.
PimozideMay enhance the CNS depressant effect of CNS Depressants.
PipotiazineMay enhance the CNS depressant effect of CNS Depressants.
PizotifenMay enhance the CNS depressant effect of CNS Depressants.
PomalidomideMay enhance the CNS depressant effect of CNS Depressants.
PosaconazoleAntifungal Agents (Azole Derivatives, Systemic) may enhance the adverse/toxic effect of Calcium Channel Blockers. Specifically, itraconazole may enhance the negative inotropic effects of verapamil or diltiazem. Antifungal Agents (Azole Derivatives, Systemic) may decrease the metabolism of Calcium Channel Blockers. Fluconazole and isavuconazonium likely exert weaker effects than other azoles and are addressed in separate monographs.
PrazosinAlpha1-Blockers may enhance the hypotensive effect of Calcium Channel Blockers.
PregabalinMay enhance the CNS depressant effect of CNS Depressants.
PrimidoneMay enhance the CNS depressant effect of CNS Depressants.
ProchlorperazineMay enhance the CNS depressant effect of CNS Depressants.
PromazineMay enhance the CNS depressant effect of CNS Depressants.
PromethazineMay enhance the CNS depressant effect of CNS Depressants.
PropofolMay enhance the CNS depressant effect of CNS Depressants.
ProtriptylineMay enhance the CNS depressant effect of CNS Depressants.
QuazepamMay enhance the CNS depressant effect of CNS Depressants.
QuetiapineMay enhance the CNS depressant effect of CNS Depressants.
RamelteonMay enhance the CNS depressant effect of CNS Depressants.
RemifentanilMay enhance the CNS depressant effect of CNS Depressants.
ReserpineMay enhance the CNS depressant effect of CNS Depressants.
RifampicinRifamycin Derivatives may decrease the serum concentration of Calcium Channel Blockers. This primarily affects oral forms of calcium channel blockers.
RifapentineRifamycin Derivatives may decrease the serum concentration of Calcium Channel Blockers. This primarily affects oral forms of calcium channel blockers.
RisperidoneMay enhance the CNS depressant effect of CNS Depressants.
RocuroniumMay enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents (Nondepolarizing).
ScopolamineMay enhance the CNS depressant effect of CNS Depressants.
SecobarbitalBarbiturates may increase the metabolism of Calcium Channel Blockers.
SevofluraneMay enhance the CNS depressant effect of CNS Depressants.
SilodosinAlpha1-Blockers may enhance the hypotensive effect of Calcium Channel Blockers.
SufentanilMay enhance the CNS depressant effect of CNS Depressants.
SulfisoxazoleMacrolide Antibiotics may decrease the metabolism of Calcium Channel Blockers.
SuvorexantMay enhance the CNS depressant effect of CNS Depressants.
TamsulosinAlpha1-Blockers may enhance the hypotensive effect of Calcium Channel Blockers.
TapentadolMay enhance the CNS depressant effect of CNS Depressants.
TelithromycinMacrolide Antibiotics may decrease the metabolism of Calcium Channel Blockers.
TemazepamMay enhance the CNS depressant effect of CNS Depressants.
TerazosinAlpha1-Blockers may enhance the hypotensive effect of Calcium Channel Blockers.
TetrabenazineMay enhance the CNS depressant effect of CNS Depressants.
ThalidomideMay enhance the CNS depressant effect of CNS Depressants.
ThioridazineMay enhance the CNS depressant effect of CNS Depressants.
ThiothixeneMay enhance the CNS depressant effect of CNS Depressants.
TiagabineMay enhance the CNS depressant effect of CNS Depressants.
TizanidineMay enhance the CNS depressant effect of CNS Depressants.
TolcaponeMay enhance the CNS depressant effect of CNS Depressants.
TopiramateMay enhance the CNS depressant effect of CNS Depressants.
TramadolMay enhance the CNS depressant effect of CNS Depressants.
TriazolamMay enhance the CNS depressant effect of CNS Depressants.
TrifluoperazineMay enhance the CNS depressant effect of CNS Depressants.
TrimipramineMay enhance the CNS depressant effect of CNS Depressants.
TriprolidineMay enhance the CNS depressant effect of CNS Depressants.
VecuroniumMay enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents (Nondepolarizing).
VigabatrinMay enhance the CNS depressant effect of CNS Depressants.
VoriconazoleAntifungal Agents (Azole Derivatives, Systemic) may enhance the adverse/toxic effect of Calcium Channel Blockers. Specifically, itraconazole may enhance the negative inotropic effects of verapamil or diltiazem. Antifungal Agents (Azole Derivatives, Systemic) may decrease the metabolism of Calcium Channel Blockers. Fluconazole and isavuconazonium likely exert weaker effects than other azoles and are addressed in separate monographs.
ZaleplonMay enhance the CNS depressant effect of CNS Depressants.
ZiconotideMay enhance the CNS depressant effect of CNS Depressants.
ZiprasidoneMay enhance the CNS depressant effect of CNS Depressants.
ZolpidemMay enhance the CNS depressant effect of CNS Depressants.
ZonisamideMay enhance the CNS depressant effect of CNS Depressants.
ZopicloneMay enhance the CNS depressant effect of CNS Depressants.
ZuclopenthixolMay enhance the CNS depressant effect of CNS Depressants.
Food InteractionsNot Available

Targets

1. Voltage-dependent calcium channel gamma-1 subunit

Kind: protein

Organism: Human

Pharmacological action: unknown

Components

Name UniProt ID Details
Voltage-dependent calcium channel gamma-1 subunit Q06432 Details

References:

  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. Pubmed
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. Pubmed

2. Voltage-dependent calcium channel subunit alpha-2/delta-1

Kind: protein

Organism: Human

Pharmacological action: unknown

Components

Name UniProt ID Details
Voltage-dependent calcium channel subunit alpha-2/delta-1 P54289 Details

References:

  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. Pubmed
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. Pubmed

3. Voltage-dependent L-type calcium channel subunit alpha-1C

Kind: protein

Organism: Human

Pharmacological action: unknown

Components

Name UniProt ID Details
Voltage-dependent L-type calcium channel subunit alpha-1C Q13936 Details

References:

  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. Pubmed
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. Pubmed

4. Voltage-dependent L-type calcium channel subunit beta-1

Kind: protein

Organism: Human

Pharmacological action: unknown

Components

Name UniProt ID Details
Voltage-dependent L-type calcium channel subunit beta-1 Q02641 Details

References:

  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. Pubmed
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. Pubmed

5. Voltage-dependent L-type calcium channel subunit beta-2

Kind: protein

Organism: Human

Pharmacological action: unknown

Components

Name UniProt ID Details
Voltage-dependent L-type calcium channel subunit beta-2 Q08289 Details

References:

  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. Pubmed
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. Pubmed

6. Voltage-dependent L-type calcium channel subunit alpha-1S

Kind: protein

Organism: Human

Pharmacological action: unknown

Components

Name UniProt ID Details
Voltage-dependent L-type calcium channel subunit alpha-1S Q13698 Details

References:

  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. Pubmed
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. Pubmed

Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on March 14, 2014 14:50